Summary
The two major biological actions of vasopressin are antidiuresis and vasoconstriction. The antidiuretic action of low concentrations of vasopressin is well established and concentrations 10 to 100 times above those required for antidiuresis elevate arterial blood pressure. Antidiuresis is mediated by V2-receptors at the kidney, whereas vasopressin constricts arterioles by binding at V1-receptors. Pharmacological effects of specific antagonists of the vasoconstrictor activity of vasopressin (vascular or V1-receptor antagonists) are presented. Low concentrations of vasopressin do have significant hemodynamic effects. Physiological concentrations of vasopressin cause vasoconstriction and elevate systemic vascular resistance. In subjects with intact cardiovascular reflex activity, however, cardiac output falls concomitantly and blood pressure therefore does not change. In animals with baroreceptor deafferentation or in patients with blunted baroreceptor reflexes (autonomic insufficiency) a rise in plasma vasopressin causes vasoconstriction and an increase in blood pressure, because cardiac output does not fall under these conditions. Vasopressin contributes substantially via increase in systemic vascular resistance to maintain blood pressure during water deprivation. During hemorrhage and hypotension vasopressin has a major role to restore blood pressure. In experimental hypertension vasopressin contributes to the development and maintenance of high blood pressure in DOCA, but not in genetic hypertensive rats. The role of vasopressin in human hypertension is not yet clear. Vasopressin in extrahypothalamic areas of the brain affects circulatory regulation by interaction with central cardiovascular control centers. The exact mechanism of how vasopressin is involved in central regulation of blood pressure remains to be established. In contrast to our previous opinion vasopressin is a vasoactive hormone also at low plasma concentrations. Its cardiovascular action is more complex than previously assumed.
Similar content being viewed by others
Abbreviations
- cAMP:
-
cyclisches Adenosinmonophosphat
- cDNA:
-
complementäre Desoxyribonucleinsäure
- d(CH2)5 :
-
1-β-Mercapto-β,β-Cyclopentamethylenpropionsäure
- d(CH2)5AVP:
-
(1-β-Mercapto-β,β-Cyclopentamethylenpropionsäure)-Arginin-Vasopressin
- d(CH2)5Tyr(Me)AVP:
-
(1-β-Mercapto-β,β-Cyclopentamethylenpropionsäure)-2-O-Methyltyrosin)-Arginin-Vasopressin
- d(CH2)5VDAVP:
-
(1-β-Mercapto-β,β-Cyclopentamethylenpropionsäure-4-Valin,-8-D-Arginin)-Vasopressin
- DDAVP:
-
Deamino-8-D-Arginin-Vasopressin
- DOCA:
-
Desoxycorticosteronacetat
- dP:
-
1-Deaminopenicillamin
- dP Tyr(Me)AVP:
-
(1-Deaminopenicillamin)-(2-O-Methyltyrosin)-Arginin-Vasopressin
- dPVDAVP:
-
(1-Deaminopenicillamin, 4-Valin-8-D-Arginin)-Vasopressin
- mRNA:
-
messenger-Ribonucleinsäure
- SHRSP:
-
Spontan hypertone Ratten vom Stroke-prone-Unterstamm
- Tyr(Me):
-
Methyltyrosin
Literatur
Aisenbrey GA, Handleman WA, Arnold P, Manning M, Schrier RW (1981) Vascular effects of arginine vasopressin during fluid deprivation in the rat. J Clin Invest 67:961–968
Altura BM (1973) Selective microvascular constrictor actions of some neurohypophyseal peptides. Europ J Pharmacol 24:49–60
Altura BM, Altura BT (1977) Vascular smooth muscle and neurohypophyseal hormones. Fed Proc 36:1853–1860
Andrews CE, Brenner BM (1981) Relative contribution of arginine vasopressin und angiotensin II to maintenance of systemic arterial pressure in the anesthetized water-deprived rat. Circ Res 48:254–258
Arnauld F, Czernichow P, Fumoux F, Vincent JD (1977) The effects of hypotension and hypovolemia on the liberation of vasopressin during hemorrhage in the unanesthetized monkey. Pflügers Arch 371:193–200
Bankowski K, Manning M, Haldar J, Sawyer WH (1978) Design of potent antagonists of the vasopressor response to arginine-vasopressin. J Med Chem 21:850–853
Berecek KH, Murray RD, Gross F, Brody MJ (1982) Vasopressin and vascular reactivity in the development of DOCA hypertension in rats with hereditary diabetes insipidus. Hypertension 4:3–12
Berecek KH, Webb RL, Brody MJ (1983) Evidence for a central role for vasopressin in cardiovascular regulation. Am J Physiol 244:H852-H859
Brownstein MJ, Russell JT, Gainer H (1980) Synthesis, transport and release of posterior pituitary hormones. Science 207:373–378
Buijs RM (1978) Intra- and extrahypothalamic vasopressin and oxytocin pathways in the rat. Cell Tissue Res 192:423–435
Bussien JP, Waeber B, Nussberger J, Schaller MD, Gavras H, Hofbauer K, Brunner HR (1984) Does vasopressin sustain blood pressure of normally hydrated healthy volunteers? Am J Physiol 246:H143-H147
Ciriello J, Calaresu FR (1980) Role of paraventricular and supraoptic nuclei in central cardiovascular regulation in the cat. Am J Physiol 239:R137-R140
Costantini MG, Pearlmutter AF: Properties of the specific binding site for arginine vasopressin in rat hippocampal synaptic membranes (1984) J Biol Chem 259:11739–11745
Cowley AW (1982) Vasopressin in cardiovascular regulation. In: Cardiovascular physiology IV, International review of Physiology. Vol 26, eds. Guyton AC, Hall JE, Baltimore, University Park Press, pp 189–242
Cowley AW, Cushman WC, Quillen EW, Skelton MM, Langford HG (1981) Vasopressin elevation in essential hypertension and increased responsiveness to sodium intake. Hypertension 3 (Suppl I):I-93–I-100
Cowley AW, Merrill C, Osborn J, Barber BJ (1984) Influence of vasopressin and angiotensin on baroreflexes in the dog. Circ Res 54:163–172
Cowley AW Jr, Monos E, Guyton AC (1974) Interaction of vasopressin and the baroreceptor reflex system in the regulation of arterial blood pressure in the dog. Circ Res 34:505–514
Cowley AW, Switzer SJ, Guinn MM (1980) Evidence and quantification of the vasopressin arterial pressure control system in the dog. Circ Res 46:58–67
Crofton JT, Share L, Shade RE, Allen C, Tarnowski D (1978) Vasopressin in the rat with spontaneous hypertension. Am J Physiol 235:H361-H366
Crofton JT, Share L, Shade RE, Lee-Kwon WJ, Manning M, Sawyer WH (1979) The importance of vasopressin in the development and maintenance of DOC-salt hypertension in the rat. Hypertension 1:31–38
Dousa TP, Valtin H (1976) Cellular actions of vasopressin in the mammalian kidney. Kidney Internat 10:46–63
Dunn FJ, Brennan TJ, Nelson AE, Robertson GL (1973) The role of blood osmolality and volume in regulating vasopressin secretion in the rat. J Clin Invest 52:3212–3219
Ellis ME, Grollman A (1949) The antidiuretic hormone in the urine in experimental and clinical hypertension. Endocrinology 44:415–419
Farini F (1913) Diabete insipido ed opoterapia. Gazz Osped Clin 34:1135–1139
Frieden J, Keller AD (1954) Decreased resistance to hemorrhage in neuro-hypophysectomized dogs. Circ Res 2:214–220
Ganten D, Unger Th, Schölkens B, Rascher W, Speck G, Stock G (1981) Role of neuropeptides in regulation of blood pressure. In: Disturbances in neurogenic control of the circulation, eds. Abboud FM, Fozzard HA, Gilmore JC, Reis DJ, American Physiological Society, pp 139–151
Ganten U, Rascher W, Lang RE, Dietz R, Rettig R, Unger Th, Taugner R, Ganten D (1983) Development of a new strain of spontaneously hypertensive rats homozygous for hypothalamic diabetes insipidus. Hypertension 5 (Suppl I):I-119–I-128
Glänzer K, Prüßing B, Düsing R, Kramer HJ (1982) Hemodynamic and hormonal responses to 8-arginine-vasopressin in healthy man: effects of indomethacin. Klin Wochenschr 60:1234–1239
Heyndrickx G, Boettcher D, Vatner S (1976) Effects of angiotensin, vasopressin and methoxamine on cardiac function and blood flow distribution in conscious dogs. Am J Physiol 231:1579–1587
Hofbauer KG, Mah SC, Wood JM, Baum P, Haenni H, Kraetz J (1984) Contribution of vascular and tubular effects of arginine-vasopressin to the development of deoxycorticosterone-salt hypertension in rats. J Hypertension 2 (Supl 3):333–335
Howell WH (1898) The physiological effects of extracts of the hypophysis cerebri and infundibular body. J Exp Med 3:245–258
Imai Y, Nolan PL, Johnston CJ (1983) Restoration of suppressed baroreflex sensitivity in rats with hereditary diabetes insipidus (Brattleboro rats) by arginine-vasopressin and DDAVP. Circ Res 53:140–149
Jard S, Bockaert J (1975) Stimulus response coupling in neurohypophysical peptide target cells. Physiol Rev 55:489–536
Khokhar AM, Slater JDH (1976) Increased renal excretion of arginine-vasopressin (AVP) during mild hydropenia in young men with mild essential benign hypertension. Clin Sci Med 51:691s-694s
Khokhar AM, Slater JDH, Ma J, Ramage CM (1980) The cardiovascular effect of vasopressin in relation to its plasma concentration in man and its relevance to high blood pressure. Clin Endocrin 13:259–266
Kruszynski M, Lammek B, Manning M, Seto J, Haldar J, Sawyer WH (1980) [1-(β-mercapto-β,β-cyclopentamethylenepropionic acid),2-(O-methyl)tyrosine] arginine vasopressin and [1-(β-mercapto-β,β-cyclopentamethylenepropionic acid] arginine vasopressin, two highly potent antagonists of the vasopressor response to arginine vasopressin. J Med Chem 23:364–368
Land H, Schütz G, Schmale H, Richter D (1982) Nucleotide sequence of cloned cDNA encoding bovine arginine vasopressin-neurophysin II precursor. Nature 295:299–303
Lang RE, Rascher W, Unger Th, Ganten D (1981) Reduced content of vasopressin in the brain of spontaneously hypertensive as compared to normotensive rats. Neurosci Lett 23:199–202
Liard JF, Deriaz O, Tschopp M, Schoun J (1981) Cardiovascular effects of vasopressin infused into the vertebral circulation of conscious dogs. Clin Sci 61:345–347
Lowbridge J, Manning M, Haldar J, Sawyer WH (1978) [1-β-mercapto-β,β-cyclopentamethylenepropionic acid), 4-valine,-8-D-arginine] vasopressin, a potent and selective inhibitor of the vasopressor response to arginine vasopressin. J Med Chem 21:313–315
Manning M, Lowbridge J, Haldar J, Sawyer WH (1977a) Design of neurohypophyseal peptides that exhibit selective agonistic and antagonistic properties. Fed Proc 36:848–853
Manning M, Lowbridge J, Stier CT, Haldar J, Sawyer WH (1977b) (1-Deaminopenicillamine,-4-valine)-8-D-arginine-vasopressin, a highly potent inhibitor of the vasopressor response to arginine-vasopressin. J Med Chem 20:1228–1230
Manning M, Gzronka Z, Sawyer WH (1981) Synthesis of posterior pituitary hormones and hormone analogues. In: The Pituitary, eds. Bearwell C, Robinson G, Kent, England, Butterworths, pp 265–296
Manning M, Klis WA, Ilma A, Seto J, Sawyer WH (1982a) Design of more potent and selective antagonists of the antidiuretic responses to arginine-vasopressin devoid of antidiuretic agonism. J Med Chem 25:414–419
Manning M, Ilma A, Klis WA, Kolodziejczyk AM, Seto J, Sawyer WH (1982b) Design of more potent antagonists of the antidiuretic responses to arginine vasopressin. J Med Chem 25:45–50
Manning M, Sawyer WH (1982) Antagonists of vasopressor and antidiuretic responses to arginine vasopressin. Ann Int Med 96:520–522
Matsuguchi H, Schmid PG (1982) Pressor responses to vasopressin and impaired baroreflex function in DOC-salt hypertension. Am J Physiol 242:H44-H49
Matsuguchi H, Sharabi FM, Gordon FJ, Johnson AK, Schmid PG (1982) Blood pressure and heart rate responses to microinjection of vasopressin into the nucleus tractus solitarii region of the rat. Neuropharmacology 21:687–693
Möhring J (1978) Neurohypophyseal vasopressor principle: vasopressor hormone as well as antidiuretic hormone? Klin Wochenschr 56 (Suppl I):71–79
Möhring J, Glänzer K, Maciel JA Jr, Düsing R, Kramer HJ, Arbogast R, Koch-Weser J (1980a) Greatly enhanced pressor response to antidiuretic hormone in patients with impaired cardiovascular reflexes due to idiopathic orthostatic hypotension. J Cardiovasc Pharmacol 2:367–376
Möhring J, Möhring B, Petri M, Haack D (1977) Vasopressor role of ADH in the pathogenesis of malignant DOC hypertension. Am J Physiol 232:F260-F269
Möhring J, Kintz J, Schoun J (1979) Studies on the role of vasopressin in blood pressure control of spontaneously hypertension rats with established hypertension. J Cardiovasc Pharmacol 1:593–608
Möhring J, Kintz J, Schoun J, McNeill JR (1981) Pressor responsiveness and cardiovascular reflex activity in spontaneously hypertensive and normotensive rats during vasopressin infusion. J Cardiovasc Pharmacol 3:948–957
Möhring J, Schoun J, Kintz J, Mc Neill R (1980b) Decreased vasopressin content in brain stem of rats with spontaneous hypertension. Naunyn Schmiedeberg's Arch Pharmacol 315:83–84
Montani JP, Liard JF, Schoun J, Möhring J (1980) Hemodynamic effects of exogenous and endogenous vasopressin at low plasma concentration in conscious dogs. Circ Res 47:346–355
Morel F (1981) Sites of hormone action in the mammalian nephron. Am J Physiol 240:F159-F164
Nestor JJ, Ferger MF, Du Vigneaud V (1975) (1-β-mercapto-β,β-pentamethylenepropionic acid) oxytocin, a potent inhibitor of oxytocin. J Med Chem 18:284–287
Oliver G, Schäfer EA (1895) On the physiological actions of extracts of the pituitary body and certain other glandular organs. J Physiol (Lond) 18:277–279
Padfield PL, Brown JJ, Lever AF, Morton JJ, Robertson JIS (1976) Changes of vasopressin in hypertension: cause or effect? Lancet 1:1255–1257
Padfield PL, Brown JJ, Lever AF, Morton JJ, Robertson JIS (1981) Blood pressure in acute and chronic vasopressin excess. Studies of malignant hypertension and the syndrome of inappropriate antidiuretic hormone secretion. N Engl J Med 304:1067–1070
Page IH, Sweet JE (1937) The effect of hypophysectomy on arterial blood pressure of dogs with experimental hypertension. Am J Physiol 120:238–245
Penit J, Faure M, Jard S (1983) Vasopressin and angiotensin II receptors in rat aortic smooth muscle in culture. Am J Physiol 244:E72-E82
Quillen EW, Cowley AW (1983) Influence of volume changes on osmolality — vasopressin relationship in conscious dogs. Am J Physiol 244:H73-H79
Rabito SF, Carretero OA, Scicli AG (1981) Evidence against a role of vasopressin in the maintenance of high blood pressure in mineralocorticoid and renovascular hypertension. Hypertension 3:34–38
Rascher W, Fink B, Gross F (1982a) Increased pressor responses following microinjections of arginine vasopressin into the nucleus tractus solitarii of spontaneously hypertensive rats. Naunyn Schmiedeberg's Arch Pharmacol 319 (Suppl):R48
Rascher W, Lang RE, Fink B, Ganten D, Unger Th, Gross F (1982b) Reduced synthesis of arginine-vasopressin in spontaneously hypertensive rats. Clin Sci 63:117s-119s
Rascher W, Lang RE, Ganten D, Meffle H, Taubitz M, Unger Th, Gross F (1983) Vasopressin in deoxycorticosterone acetate hypertension of rats: a hemodynamic analysis. J Cardiovasc Pharmacol 5:418–425
Rascher W, Lang RE, Unger Th (1985) Vasopressin, cardiovascular regulation and hypertension. In: Current Topics in Neuroendocrinology, Vol 4, eds. Ganten D, Pfaff D, Heidelberg Berlin New York, Springer, pp 101–136
Rascher W, Lang RE, Unger Th, Ganten D, Gross F (1982c) Vasopressin in brain of spontaneously hypertensive rats. Am J Physiol 242:H496-H499
Rascher W, Meffle H, Gross F (1985) Hemodynamic effects of arginine-vasopressin in conscious water-deprived rats. Am J Physiol, in press
Rascher W, Weidmann E, Gross F (1981) Vasopressin in the plasma of stroke-prone spontaneously hypertensive rats. Clin Sci 61:295–298
Robertson GL (1977) The regulation of vasopressin function in health and disease. Recent Prog Horm Res 33:333–385
Robertson GL, Athar S (1976) The interaction of blood osmolality and blood volume in regulation plasma vasopressin in man. J Endocrinol Metab 42:613–620
Sawyer WH, Acosta M, Manning M (1974) Structural changes in the arginine vasopressin molecule that prolong its antidiuretic action. Endocrinology 95:140–149
Sawyer WH, Grzonka Z, Manning M (1981) Neurohypophyseal peptides: Design of tissue-specific agonists and antagonists. Mol Cell Endocrinol 22:117–134
Sawyer WH, Manning M (1973) Synthetic analogues of oxytocin and vasopressin. Ann Rev Pharm 13:5–17
Sawyer WH, Pang PKT, Seto J, McEnroe M, Lammek B, Manning M (1982) Vasopressin analogues that antagonize antidiuretic responses by rats to the antidiuretic hormone. Science 212:49–51
Schmid PG, Abboud FM, Wendling MG, Ramberg ES, Mark AL, Heistad DD, Eckstein JW (1974) Regional vascular effects of vasopressin: plasma levels and circulatory responses. Am J Physiol 227:998–1004
Schrier RW, Berl T, Anderson RJ (1979) Osmotic and nonosmotic release of vasopressin. Am J Physiol 236:F321-F332
Schulz H, Du Vigneaud V (1966) Synthesis of (1-l-penicillamine)oxytocin, (1-d-penicillamine)oxytocin and (1-deaminopenicillamine)oxytocin, potent inhibitor of the oxytocin response to oxytocin. J Med Chem 9:647–650
Schwartz J, Reid IA (1981) Effect of vasopressin blockade on blood pressure regulation during hemorrhage in conscious dogs. Endocrinology 109:1778–1780
Smith MJ, Cowley AW, Guyton AC, Manning RD (1979) Acute and chronic effects of vasopressin on blood pressure, electrolytes and fluid volumes. Am J Physiol 237:F232-F240
Sofroniew MV, Weindl A (1978) Projections from the parvocellular vasopressin- and neurophysin-containing neurons of the suprachiasmatic nucleus. Am J Anat 153:391–401
Swanson LW (1977) Immunohistochemical evidence for a neurophysin containing autonomic pathway in the paraventricular nucleus of the hypothalamus. Brain Res 128:346–353
Szczepanska-Sadowska E (1973) Hemodynamic effects of a moderate increase of the plasma vasopressin level in conscious dogs. Pflügers Arch 338:313–322
Unger Th, Rohmeiss P, Becker H, Ganten D, Lang RE, Petty M (1984) Sympathetic activation following cental vasopressin receptor stimulation in conscious rats. J Hypertension 2 (Suppl 3):25–27
Versteeg CAM, Bohus B, de Jong W (1982) Inhibition of centrally evoked pressor responses by neurohypophyseal peptides and their fragments. Neuropharmacology 21:1359–1364
Von den Velden R (1913) Die Nierenwirkung von Hypophysenextrakten bei Menschen. Berlin Klin Wochenschr 50:2083–2086
Walter R (1975) Neurophysins: carriers of peptide hormones. Ann NY Acad Sci 248:1–512
Weitzman RE, Fisher DA, DiStefano JJ, Bennett CM (1977) Episodic secretion of arginine vasopressin. Am J Physiol 233:E32-E36
Weitzman RE, Reviczky A, Oddie TH, Fisher DA (1980) Effect of osmoality on arginine vasopressin and renin release after hemorrhage. Am J Physiol 238:E62-E68
Young DB, Pan YJ, Guyton AC (1977) Control of extracellular sodium concentration by antidiuretic hormone-thirst feedback mechanism. Am J Physiol 232:R145-R149
Zerbe RL, Feuerstein G, Meyer DK, Kopin IJ (1982) Cardiovascular, sympathetic, and renin-angiotensin system responses to hemorrhage in vasopressin-deficient rats. Endocrinology 111:608–613
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rascher, W. Kardiovaskuläre Wirkung des antidiuretischen Hormons Arginin-Vasopressin. Klin Wochenschr 63, 989–999 (1985). https://doi.org/10.1007/BF01737635
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01737635